Kiniksa Pharmaceuticals International Plc Q3 FY2026 earnings call

• Commercial Execution: Arcus penetration into the multiple recurrence patient population reached 23% by end of Q3, up from 18% at the end of 2025. Prescriber base expanded to approximately 5,450 physicians, with a quarterly increase of 450 new prescribers.
• Market Dynamics: Adoption is shifting earlier in the treatment line; approximately 50% of surveyed physicians now support using IL-1 alpha/beta inhibition prior to corticosteroids, following 2025 ACC guidelines. Roughly 20% of prescriptions now target first-recurrence patients.
• Digital Strategy: The 'Heart's Home' direct-to-consumer campaign utilizing AI targeting has resulted in a 12-fold increase in website traffic and an 8-fold increase in engaged sessions. Approximately 55% of exposed patients reported motivation to discuss Arcus with their providers.
• Pipeline Progress: KPL-387 pivotal Phase 3 study is enrolling globally, with data expected in H2 2027. KPL-1161 is on track to enter Phase 1 trials by the end of 2026.
• Financial Health: The company generated approximately $43 million in net cash during Q3, ending with $568.8 million in cash. Operating income rose to $54.2 million and net income to $47.3 million, both significantly up year-over-year.

Connexa Pharmaceuticals reported strong financial performance driven by its primary product, Arcus (Arcos/Arclis). In the third quarter of 2026, Arcus revenue grew 58% year-over-year to $286 million. This segment represents the entirety of the company's current commercial revenue, as other assets are in clinical development. The company raised its full-year Arcus revenue guidance for 2026 to between $1.045 billion and $1.050 billion, indicating that Arcus will contribute nearly 100% of total corporate revenue for the fiscal year.

• Revenue: Full-year 2026 Arcus revenue guidance was raised to $1.045–$1.050 billion.
• R&D Expenses: Full-year 2026 R&D expenses are guided at $160–$170 million, reflecting continued development of KPL-387 and KPL-1161, plus significant pre-commercial manufacturing costs for KPL-387 in Q4.
• SG&A Expenses: Full-year 2026 SG&A expenses are guided at $270–$280 million, supporting expanded commercialization efforts, personnel, and promotional activities in Q4.

• Clinical Development Uncertainty: Results for KPL-387 and KPL-1161 are subject to clinical trial outcomes; failure or delay could impact future growth and valuation.
• Competition and Market Penetration: Despite strong growth, only 23% of the target multiple-recurrence population is treated, implying competitive barriers or access challenges remain for the remaining 77%.
• Regulatory Labeling: The success of KPL-387 depends on favorable labeling regarding transition regimens and dosing, which is still being determined through ongoing studies.
• Capital Allocation: Management notes that while BD opportunities are considered, the bar for external acquisitions is exceedingly high, limiting immediate M&A-driven value creation.

Q: Anupam Rama asked about KPL-387 enrollment dynamics and site initiation confidence given the new H2 2027 data timeline.

A: CEO Sanj Patel highlighted global execution momentum and investigator engagement. CMO John Paolini added that clinicaltrials.gov lists extensive global sites, confirming robust scope and excitement among clinicians, validating the timeline.

Q: Edward Nash inquired about the shape of the penetration curve beyond 23%, asking if next-quartile patients differ structurally or require higher SG&A spend.

A: COO Ross Moat noted no significant demographic changes in patient profiles but emphasized the large untapped market in both multi-recurrence and first-recurrence groups. He stressed that DTC and field spend are highly efficient, targeted investments rather than broad-spectrum expenditures.

Q: Paul Choi asked for details on KPL-387’s target product profile for insurance approval and KPL-1161’s indication selection.

A: Paolini explained KPL-387’s pivotal study is a posology study focusing on transitioning stable patients to monthly subcutaneous monotherapy. Moat added that patient feedback favors the monthly liquid/auto-injector format, with 92% of HCPs likely to prescribe it, though data remains key. For KPL-1161, Paolini indicated indications are not yet disclosed but focus on chronic conditions due to quarterly dosing potential.

Q: Roger Song’s representative asked about new patient sources (first-time vs. repeat) and growth in first-recurrence patients.

A: Moat declined to share exact splits but noted ~5,450 total prescribers, with ~30% being repeat prescribers. Historically, ~80% of scripts go to second-plus recurrence patients and ~20% to first recurrence, with recent growth driven by refined targeting and guideline dissemination.

Q: Jeff Meacham asked about specific patient attributes suited for KPL-387 transition and capital deployment priorities.

A: Paolini stated KPL-387 offers optionality for patients/stable on various therapies to transition to monthly monotherapy, with efficacy still pending. Patel emphasized pragmatic capital allocation, noting high bars for BD deals, and prioritizing internal pipeline execution and organic growth over acquisitions.